MEI Pharma is in defense mode after activist investors called for the removal of the San Diego biotech’s entire board and a cash return to shareholders.
READ MOREAfter the pandemic spurred a rush to digital commercialization strategies, pharma companies realized they needed to evolve their traditional sales rep-led models. However, they’re still ...
READ MOREThe FDA has lifted a temporary clinical hold on EryDel’s IND for its rare disease drug-device product, boding well for California biotech Quince Therapeutics, which is set to acquire ...
READ MOREThe FDA acknowledged today that it's been allowing temporary imports of the commonly used cancer drug cisplatin from Fresenius Kabi to help shore up the continuing shortage of the drug ...
READ MORE
